A 96% Cure for Sickle Cell Disease Worked. The Company That Made It Killed It Anyway.

On April 1, 2026, the New England Journal of Medicine published the results of a clinical trial that should have been a triumph: twenty-eight people with severe sickle cell disease received reni-cel, a CRISPR-Cas12a gene therapy developed by Editas Medicine, and twenty-seven of them never had another sickle cell crisis. Hemoglobin levels normalized. Fetal hemoglobin, which protects against sickling, surged from a baseline of 2.5% to 48.1%, a concentration so high that the sickle mutation is functionally silenced. By every clinical measure that matters to a person living with a disease that causes unbearable pain, organ damage, and early death, reni-cel worked.

Buried in the methods section is a sentence that reads like a footnote but functions as an epitaph: "The study was terminated early on the basis of the sponsor's reassessment of clinical development priorities."

In December 2024, three months before these results reached a journal, Editas Medicine laid off 65% of its workforce, discontinued reni-cel, and pivoted to an entirely different technology platform because it couldn't find a commercial partner and its market capitalization had fallen below the cost of a single Phase 3 trial. A therapy that functionally cured 96% of its patients was orphaned not because it failed, but because its maker ran out of money.

What Reni-cel Did

Sickle cell disease is caused by a single amino acid substitution in the hemoglobin gene that deforms red blood cells into rigid crescents, which clog capillaries and trigger vaso-occlusive crises: episodes of excruciating pain that send patients to emergency departments an average of five times per year. Roughly 100,000 Americans live with this disease, more than 90% of them Black, and until recently the standard of care consisted of hydroxyurea, blood transfusions, and pain management with opioids.

Reni-cel took a fundamentally different molecular path than its better-known competitor, Vertex's Casgevy, which uses CRISPR-Cas9 to disrupt a BCL11A enhancer and thereby reduce production of a fetal-hemoglobin repressor. Reni-cel instead uses Cas12a, a smaller, structurally distinct enzyme, to edit two promoter regions, HBG1 and HBG2, directly, reactivating fetal hemoglobin production at the source rather than suppressing a repressor upstream. Both strategies converge on the same therapeutic destination; the molecular routes diverge completely.

In the RUBY trial, 28 patients between ages 12 and 50 received a single infusion of reni-cel after myeloablative conditioning with busulfan, and the results at six months were striking: mean total hemoglobin had risen from 9.8 to 13.8 grams per deciliter, squarely within the normal range for healthy adults, while fetal hemoglobin jumped from 2.5% to 48.1%. Neutrophil and platelet engraftment occurred within clinically expected windows for all 27 patients who had engrafted by the data cutoff. One patient experienced two vaso-occlusive events after infusion. Twenty-seven experienced none.

Editas ran a parallel trial in patients with transfusion-dependent beta-thalassemia, called EdiTHAL, whose results, also published in the NEJM, showed durable engraftment, high fetal hemoglobin levels, and complete elimination of the need for regular blood transfusions. Both trials were terminated early by Editas.

Why Editas Killed It

Editas Medicine entered 2024 with approximately $270 million in cash, a Phase 1-2 trial producing extraordinary data, and no partner willing to share the cost of what came next. Completing development would have required a Phase 3 trial, manufacturing scale-up, and regulatory submissions, a process that typically costs $300 to $500 million for a cell therapy, and the company's entire market capitalization was roughly $185 million, less than half the remaining price tag.

In the fall of 2024, Editas tried to find a pharmaceutical partner willing to co-develop or license reni-cel, but nobody bit: Vertex and CRISPR Therapeutics already had Casgevy on the market with FDA approval and a head start that would be nearly impossible to close, and no large pharma company wanted to invest hundreds of millions in a second-to-market Cas12a therapy when the Cas9 version was already generating revenue. CEO Gilmore O'Neill announced the pivot in December, framing it as forward-looking optimism about in vivo gene editing rather than a retreat forced by insolvency. "Recent scientific breakthroughs by the Editas team have convinced us that the timelines around the near-term viability of in vivo CRISPR-edited medicines have accelerated meaningfully," he said. Restructuring charges totaled $53.1 million, the remaining cash runway extends into Q3 2027, and by early 2026 the stock had collapsed to $2.20 per share.

258 Patients to Break Even

Here is the question that Editas's board apparently never answered publicly, and it has a specific number attached to it: how many patients would reni-cel have needed to treat to justify completing development?

Start with costs. A conservative estimate for completing Phase 3, scaling manufacturing, and obtaining FDA approval comes to roughly $400 million, based on comparable cell therapy programs that have navigated this path. Manufacturing cost per patient for an ex vivo cell therapy involving apheresis, CD34+ isolation, CRISPR editing, quality testing, cryopreservation, and cold-chain shipping runs approximately $650,000. At Casgevy's list price of $2.2 million per treatment, that yields a gross margin of roughly $1.55 million per patient, and dividing $400 million by $1.55 million produces the answer: 258 patients, representing just 1.2 to 1.6% of the estimated 16,000 to 21,500 eligible Americans with severe sickle cell disease who experience at least two vaso-occlusive crises per year.

Metric	Value	Source
Remaining development cost (est.)	$400M	Comparable cell therapy programs
Manufacturing COGS per patient	~$650K	Industry estimates, ex vivo cell therapy
Treatment price (Casgevy benchmark)	$2.2M	Vertex list price
Gross margin per patient	$1.55M	Calculated
Patients to break even	258	Calculated
Eligible U.S. SCD population	16,000–21,500	Vertex filings, CDC data
Break-even as % of eligible	1.2–1.6%	Calculated

Now consider the other side of the ledger, denominated not in shareholder returns but in human suffering averted. Patients with sickle cell disease and recurrent vaso-occlusive crises incur average annual healthcare costs of $67,282 per year, compared to $4,134 for matched controls, according to a 2023 study in Advances in Therapy analyzing 3,420 patients in the MarketScan claims database across nearly a decade of follow-up. Over 50 years, cumulative healthcare costs for a patient with recurrent crises reach $3.8 million versus $229,000 for controls. A one-time $2.2 million treatment that eliminates crises saves the healthcare system $1.16 million per patient over a lifetime, net of the treatment cost, and if 10,000 patients were treated over reni-cel's commercial life, aggregate savings would approach $11.6 billion.

Put differently: that $400 million Editas couldn't raise represents 3.4% of the societal savings reni-cel could have generated. A company valued at $185 million was sitting on a program whose conservative actuarial value to the healthcare system exceeded its entire market capitalization by orders of magnitude, but that value accrues to insurers, hospitals, and patients over decades, not to a biotech's quarterly income statement.

Two Scissors, One Answer

If reni-cel's clinical data look familiar, that is because they are nearly identical to Casgevy's. Vertex's Phase 3 trial of exa-cel in 44 sickle cell patients, published in the NEJM in 2024, reported that 29 of 30 evaluable patients (97%) were free from vaso-occlusive crises for at least 12 consecutive months, while reni-cel's RUBY trial found 27 of 28 (96%) crisis-free after a median follow-up of 9.5 months. Both therapies raised fetal hemoglobin above 40%, both normalized total hemoglobin, both used busulfan conditioning, and both achieved rapid engraftment within the same clinical windows.

Cas12a recognizes T-rich PAM sequences and processes its own guide RNA; Cas9 recognizes G-rich PAM sequences and requires a separate tracrRNA. Reni-cel edits at HBG1 and HBG2 promoters; Casgevy edits at a BCL11A enhancer. Two independent research teams used two different molecular scissors at two entirely different locations in the genome and converged on a result so similar that you cannot distinguish the clinical outcomes in a blinded comparison. Sickle cell disease, it turns out, is solved twice over, a redundancy that should inspire confidence in the underlying biology even as it makes the commercial case for the second entrant nearly impossible to sustain.

A Structural Mismatch

Editas's collapse is not a story about one company making bad decisions; it is a case study in a structural incompatibility between how gene therapies are developed and how they generate value. Drug development in the United States is financed by venture capital and public equity markets that expect returns within five to ten years, but gene therapies for rare diseases take a decade to develop and generate value over the patient's remaining lifetime, which is 40 to 60 years for a teenager treated for sickle cell disease. Capital markets and therapeutic timelines are mismatched by a factor of five.

What follows from this mismatch is predictable and grim. A company spends $400 million developing a therapy that works in 96% of patients, but completing the program requires another $400 million, and the stock market values the company at $185 million because it is pricing the probability-weighted net present value of distant cash flows, discounted at the punishing rates applied to clinical-stage biotechs with no revenue. NEJM data say the therapy works; capital markets say it doesn't matter.

Vertex, by contrast, is primarily a cystic fibrosis franchise with $9.9 billion in annual revenue that could finance Casgevy's Phase 3 development from operating cash flow without needing a partner, without facing an existential choice between finishing the trial and keeping the lights on. Reni-cel did not lose because Cas12a is inferior to Cas9. It lost because Editas is not Vertex.

Limitations

Several important caveats apply to this analysis. Reni-cel's RUBY trial was Phase 1-2 with a median follow-up of 9.5 months, so long-term durability beyond two years is unknown, and Phase 3 results could have diverged from early-stage data in ways that would have reduced or eliminated the 96% efficacy signal. Break-even calculations assume Casgevy-equivalent pricing, but a second-to-market therapy might have faced payer resistance and significant price erosion that would stretch the break-even horizon. Manufacturing cost estimates of $650,000 per patient are approximate, drawn from industry comparisons rather than Editas's actual production economics, and actual COGS for a novel Cas12a platform could have been substantially higher. Eligible-patient-population estimates rely on aggregate epidemiological data rather than clinical screening, and Editas may have faced undisclosed IP complications or manufacturing feasibility challenges beyond what it publicly acknowledged. Societal savings capture only direct healthcare costs, excluding lost productivity, caregiver burden, and quality-of-life value, all of which would increase the total economic benefit of treatment.

What You Can Do

If you have sickle cell disease or care for someone who does, Casgevy is FDA-approved and available at approximately 50 treatment centers in the United States for patients aged two and older, with insurance coverage reaching about 90% of eligible patients. Ask your hematologist for a referral and do not wait for a second therapy that may never arrive. Reni-cel's data, though orphaned, independently confirm that fetal hemoglobin reactivation is a durable strategy across different CRISPR platforms, which should increase confidence that Casgevy's mechanism is not a fluke of one particular enzyme.

If you work in health policy or pharmaceutical investment, reni-cel is a case study in a market failure that will recur with increasing frequency as gene therapy pipelines expand into rare diseases where the biology works but the economics of small-company drug development do not. Mechanisms that bridge this gap, whether advance market commitments, government-backed development funds, or large-pharma licensing frameworks with milestone payments calibrated to clinical-stage risk, could prevent future orphaning of viable therapies, and the chasm between a 258-patient break-even and a 16,000-patient addressable market reveals an incentive structure that failed by a margin too wide to dismiss.

The Bottom Line

Twenty-seven people are walking around right now with normalized hemoglobin, zero sickle cell crises, and a therapy inside their bone marrow that their own maker decided was not worth finishing. Reni-cel is the most effective CRISPR therapy ever tested for sickle cell disease that will never reach a pharmacy, and if you want to understand why gene therapy has not yet delivered on its promise for the people who need it most, do not look at the science, because the science worked. Look at the balance sheet of a company that was worth less than the clinical trial it would have needed to prove what it already knew.